Ideal outcome post-pancreatoduodenectomy: a comprehensive healthcare system analysis

• Published in: Langenbeck's archives of surgery 2024-11, Vol.409 (1), p.339, Article 339
• Main Authors: Khalid, Abdullah, Pasha, Shamsher A., Demyan, Lyudmyla, Newman, Elliot, King, Daniel A., DePeralta, Danielle, Gholami, Sepideh, Weiss, Matthew J., Melis, Marcovalerio
• Format: Article
• Language: English
• Subjects: Abdominal Surgery; Adult; Aged; Cardiac Surgery; Female; General Surgery; Hospital Mortality; Humans; Male; Medicine; Medicine & Public Health; Middle Aged; Outcome Assessment, Health Care; Pancreatic Neoplasms - mortality; Pancreatic Neoplasms - surgery; Pancreaticoduodenectomy - adverse effects; Postoperative Complications - epidemiology; Retrospective Studies; Thoracic Surgery; Traumatic Surgery; Treatment Outcome; Vascular Surgery
• ISSN: 1435-2451; 1435-2451
• DOI: 10.1007/s00423-024-03532-4

Introduction Indicators, such as mortality and complications, are commonly used to measure the quality of care. However, a more comprehensive assessment of surgical quality is captured using composite outcome measures such as Textbook Outcome (TO), Optimal Pancreatic Surgery, and a newer ‘Ideal Outcome’ (IO) measure. We reviewed our institutional experience to assess the impact of demographics, comorbidities, and operative variables on IO after pancreatoduodenectomy (PD). Methods A retrospective study was conducted on PD patients at Northwell Health between 2009 and 2023. IO was determined by the absence of six adverse outcomes, including in-hospital mortality, Clavien-Dindo ≥ III complications, clinically-relevant postoperative pancreatic fistula, reoperation, hospital stay > 75th percentile, and readmission within 30 days. Logistic regression analyzed the effects of various factors on achieving IO. Results Of the 578 patients who underwent PD, 248 (42.91%) achieved the IO. On multivariable analysis, factors associated with increased odds of achieving IO included neoadjuvant chemotherapy (OR 1.30, 95% CI 1.05–1.62) and the presence of neuroendocrine tumors (OR 3.37, 95% CI 1.35–8.41). Percutaneous transhepatic biliary drainage (PTBD) (OR 0.34, 95% CI 0.14–0.80) and older age (≥ 70 years) (OR 0.48, 95% CI 0.32–0.74) were associated with decreased odds of achieving IO. Patients with IO had significantly improved survival on Kaplan-Meier log-rank test ( p  = 0.001) as well as adjusted Cox analysis (HR 0.62 95% CI: 0.39–0.97). Conclusion IO may offer a comprehensive metric for assessing PD outcomes, highlighting the impact of age, chemotherapy, biliary drainage, and tumor types. These findings suggest targeted interventions and quality improvements could enhance PD outcomes by addressing modifiable factors and refining clinical strategies.